GE, VirtualScopics to study PET biomarkers
VirtualScopics is partnering with GE Healthcare's Medical Diagnostics Imanet unit to study PET imaging biomarkers used in drug development.

The collaboration of VirtualScopics and GE's Imanet would provide customers in vivo detection and advanced analysis of more than 40 PET imaging biomarkers for drug research in a variety of disease pathways, including oncology, said the Rochester, N.Y.-based VirtualScopics. The combined competencies of both companies in PET, MRI, CT and ultrasound could help play a role in identifying targets for patient stratification and treatment, the company added.